IL-1Ra and its delivery strategies: Inserting the association in perspective

Pharmaceutical Research

Volumn 30, Issue 11, 2013, Pages 2951-2966

  Akash, Muhammad Sajid Hamid ^a,b   Rehman, Kanwal ^a   Chen, Shuqing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

Author keywords

delivery strategies; encapsulation of IL 1Ra; fusion of IL 1Ra; sustained release of IL 1Ra; thermosensitive gel

Indexed keywords

AGGRECANASE 1; ALBUMIN ANTIBODY; DEXTRAN; ELASTIN; HUMAN SERUM ALBUMIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROGOL; MICROSPHERE; POLYMER; POLYPEPTIDE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

AMINO TERMINAL SEQUENCE; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTHRITIS; BINDING AFFINITY; BIODEGRADABILITY; CARBOXY TERMINAL SEQUENCE; CARTILAGE CELL; CELL PROLIFERATION; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RELEASE; ENCAPSULATION; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION; GLYCOSYLATION; HEAT SENSITIVITY; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LONGEVITY; LYMPHOCYTE PROLIFERATION; MUCOSAL ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; PHASE TRANSITION; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MOTIF; REVIEW; THYMOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN;

EID: 84886098158     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1118-0     Document Type: Review

References (129)

1. Freeman BD, Buchman TG. Interleukin-1 receptor antagonist as therapy for inflammatory disorders. Expert Opin Biol Ther. 2001;1:301-8.
2. Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol. 2007;149:217-25.
3. Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv Ther. 2006;23:208-17.
4. Akash MSH, Shen Q, Rehman K, Chen S. Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus. J Pharm Sci. 2012;101:1647-58.
5. Akash MSH, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2013;114:525-31.
6. Akash MSH, Rehman K, Chen S. An overview of valuable scientific models for diabetes mellitus. Curr Diabetes Rev. 2013;9:286-93.
7. Lee BC, Ahn SY, Doo HK, Yim SV, Lee HJ, Jin SY, et al. Susceptibility for ischemic stroke in Korean population is associated with polymorphisms of the interleukin-1 receptor antagonist and tumor necrosis factor-alpha genes, but not the interleukin-1beta gene. Neurosci Lett. 2004;357:33-6.
8. Pinteaux E, Rothwell NJ, Boutin H. Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia. 2006;53:551-6.
9. Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003;74:788-9.
10. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK. Sustained Hippocampal IL-1beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest. 2007;117:1595-604.
11. Ferrari CC, Pott Godoy MC, Tarelli R, Chertoff M, Depino AM, Pitossi FJ. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol Dis. 2006;24:183-93.
12. Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain. 2008;131:1880-94.
13. Bartfai T, Sanchez-Alavez M, Andell-Jonsson S, Schultzberg M, Vezzani A, Danielsson E, et al. Interleukin-1 system in CNS stress: seizures, fever, and neurotrauma. Ann N Y Acad Sci. 2007;1113:173-7.
14. Simi A, Tsakiri N, Wang P, Rothwell NJ. Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans. 2007;35:1122-6.
15. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol. 2007;208:1-25.
16. McColl BW, Allan SM, Rothwell NJ. Systemic infection, inflammation and acute ischemic stroke. Neuroscience. 2009;158:1049-61.
17. Vezzani A, Balosso S, Maroso M, Zardoni D, Noe F, Ravizza T. ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. Curr Opin Investig Drugs. 2010;11:43-50.
18. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005;5:629-40.
19. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol. 2006;147:S232-40.
20. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62:258-67.
21. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22:868-76.
22. Cawthorne C, Prenant C, Smigova A, Julyan P, Maroy R, Herholz K, et al. Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [(1)(8)F]-IL1RA and PET imaging in rats. Br J Pharmacol. 2011;162:659-72.
23. Parveen A, Akash MSH, Rehman K, Tariq M, Zahara N, Iqbal T. Biodisposition kinetics of isoniazid in healthy females. J App Pharm. 2012;4:676-81.
24. Rehman K, Akash MSH, Azhar S, Khan SA, Abid R, Waseem A, et al. A biochemical and histopathologic study showing protection and treatment of gentamicin-induced nephrotoxicity in rabbits using vitamin C. Afr J Tradit Complement Altern Med. 2012;9:360-5.
25. Bellingham CM, Lillie MA, Gosline JM, Wright GM, Starcher BC, Bailey AJ, et al. Recombinant human elastin polypeptides self-assemble into biomaterials with elastin-like properties. Biopolymers. 2003;70:445-55.
26. Wise SG, Mithieux SM, Raftery MJ, Weiss AS. Specificity in the coacervation of tropoelastin: solvent exposed lysines. J Struct Biol. 2005;149:273-81.
27. Chow D, Nunalee ML, Lim DW, Simnick AJ, Chilkoti A. Peptide-based biopolymers in biomedicine and biotechnology. Mater Sci Eng R Rep. 2008;62:125-55.
28. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6:688-701.
29. McDaniel JR, Callahan DJ, Chilkoti A. Drug delivery to solid tumors by elastin-like polypeptides. Adv Drug Deliv Rev. 2010;62:1456-67.
30. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2001;47:113-31.
31. Chuang VTG, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res. 2002;19:569-77.
32. Martino M, Tamburro AM. Chemical synthesis of cross-linked poly(KGGVG), an elastin-like biopolymer. Biopolymers. 2001;59:29-37.
33. Martino M, Coviello A, Tamburro AM. Synthesis and structural characterization of poly(LGGVG), an elastin-like polypeptide. Int J Biol Macromol. 2000;27:59-64.
34. Spezzacatena C, Perri T, Guantieri V, Sandberg LB, Mitts TF, Tamburro AM. Classical synthesis of and structural studies on a biologically active heptapeptide and a nonapeptide of bovine elastin. Eur J Org Chem. 2002;2002:95-103.
35. Betre H, Liu W, Zalutsky MR, Chilkoti A, Kraus VB, Setton LA. A thermally responsive biopolymer for intra-articular drug delivery. J Control Release. 2006;115:175-82.
36. Meyer DE, Chilkoti A. Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat Biotechnol. 1999;17:1112-5.
37. Shamji MF, Betre H, Kraus VB, Chen J, Chilkoti A, Pichika R, et al. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local anti-inflammatory therapeutic. Arthritis Rheum. 2007;56:3650-61.
38. Kim DH, Smith JT, Chilkoti A, Reichert WM. The effect of covalently immobilized rhIL-1ra-ELP fusion protein on the inflammatory profile of LPS-stimulated human monocytes. Biomaterials. 2007;28:3369-77.
39. Christensen T, Amiram M, Dagher S, Trabbic-Carlson K, Shamji MF, Setton LA, et al. Fusion order controls expression level and activity of elastin-like polypeptide fusion proteins. Protein Sci. 2009;18:1377-87.
40. Huang YS, Chen Z, Yang ZY, Wang TY, Zhou L, Wu JB, et al. Preparation and characterization of a potent, long-lasting recombinant human serum albumin-interferon-alpha2b fusion protein expressed in Pichia pastoris. Eur J Pharm Biopharm. 2007;67:301-8.
41. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S, McHutchison JG. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol. 2007;25:1411-9.
42. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Contr Release. 2008;132:171-83.
43. Dou WF, Lei JY, Zhang LF, Xu ZH, Chen Y, Jin J. Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris. Protein Expr Purif. 2008;61:45-9.
44. Chen JH, Zhang XG, Jiang YT, Yan LY, Tang L, Yin YW, et al. Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris. Canc Immunol Immunother. 2010;59:1335-45.
45. Muller D, Karle A, Meißburger B, Hofig I, Stork R, Kontermann RE. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem. 2007;282:12650-60.
46. Yazaki PJ, Kassa T, Cheung CW, Crow DM, Sherman MA, Bading JR, et al. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol. 2008;35:151-8.
47. Evans L, Hughes M, Waters J, Cameron J, Dodsworth N, Tooth D, et al. The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr Purif. 2010;73:113-24.
48. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther. 2002;303:540-8.
49. Dai SF, Shen Q, Chen S. Inhomogeneous expression of fusion protein HSA/IL-1RaPichia pastoris. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2008;37:134-8.
50. Shen Q, Chen S. Purification of fusion protein HSA/IL-1Ra and its bioactivity. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009;38:260-4.
51. Kobayashi K, Kuwae S, Ohya T, Ohda T, Ohyama M, Ohi H, et al. High-level expression of recombinant human serum albumin from the methylotrophic yeast Pichia pastoris with minimal protease production and activation. J Biosci Bioeng. 2000;89:55-61.
52. Kang HA, Kang W, Hong WK, Kim MW, Kim JY, Sohn JH, et al. Development of expression systems for the production of recombinant human serum albumin using the MOX promoter in hansenula polymorphaDL-1. Biotechnol Bioeng. 2001;76:175-85.
53. Marx H, Mecklenbrauker A, Gasser B, Sauer M, Mattanovich D. Directed gene copy number amplification in Pichia pastoris by vector integration into the ribosomal DNA locus. FEMS Yeast Res. 2009;9:1260-70.
54. Sung C, Nardelli B, LaFleur DW, Blatter E, Corcoran M, Olsen HS, et al. An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. J Interferon Cytokine Res. 2003;23:25-36.
55. Wang W, Ou Y, Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res. 2004;21:2105-11.
56. Duttaroy A, Kanakaraj P, Osborn BL, Schneider H, Pickeral OK, Chen C, et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes. 2005;54:251-8.
57. Shen Q, Wu M, Wang H, Naranmandura H, Chen S. The effect of gene copy number and co-expression of chaperone on production of albumin fusion proteins in Pichia pastoris. Appl Microbiol Biotechnol. 2012;96:763-72.
58. Jespers L, Schon O, Famm K, Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol. 2004;22:1161-5.
59. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989;341:544-6.
60. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel. 2008;21:283-8.
61. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151:1548-61.
62. Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003;197:315-22.
63. Beninati C, Oggioni MR, Boccanera M, Spinosa MR, Maggi T, Conti S, et al. Therapy of mucosal candidiasis byexpression of an anti-idiotype in human commensal bacteria. Nat Biotechnol. 2000;18:1060-4.
64. Kruger C, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D, et al. In situ delivery of passiveimmunity by lactobacilli producing single-chain antibodies. Nat Biotechnol. 2002;20:702-6.
65. Steidler L, Robinson K, Chamberlain LM, Schofield KM, Remaut E, Le Page RWF, et al. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun. 1998;66:3183-9.
66. Bermudez-Humaran LG, Langella P, Cortes-Perez NG, Gruss A, Tamez-Guerra RS, Oliveira SC, et al. Intranasal immunization with recom-binant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun. 2003;71:1887-96.
67. Medaglini D, Oggioni MR, Pozzi G. Vaginal immunization with recombinant gram positive bacteria. Am J Reprod Immunol. 1998;39:199-208.
68. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lac-tis secreting interleukin-10. Science. 2000;289:1352-5.
69. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, God-deeris B, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol. 2003;21:785-9.
70. Ricci S, Macchia G, Ruggiero P, Maggi T, Bossù P, Xu L, et al. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii. BMC Biotechnol. 2003;3:15.
71. Porzio S, Bossù P, Ruggiero P, Boraschi D, Tagliabue A. Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria. BMC Biotechnol. 2004;4:27.
72. Shah SNH, Asghar S, Choudhry MA, Akash MSH, Rehman NU, Baksh S. Formulation and evaluation of natural gum-based sustained release matrix tablets of flurbiprofen using response surface methodology. Drug Develop Ind Pharm. 2009;35:1470-8.
73. Akash MSH, Iqbal F, Raza M, Rehman K, Ahmed S, Shahzad Y, et al. Characterization of ethylcellulose and hydroxypropyl methylcelluse microspheres for controlled release of flurbiprofen. J Pharm Drug Deliv Res. 2013. doi: 10.4172/2325-9604.1000113.
74. Shah SNH, Shahzad Y, Akash MSH, Ali M, Salman M, Bukhari SNI, et al. Rabbit skin and polydimethylsiloxane as model membranes to evaluate permeation kinetics from topical formulation. Pak J Zoo. 2013;45:159-66.
75. Stratton LP, Dong A, Manning M, Carpenter JF. Drug delivery matrix containing native protein precipitates suspended in a poloxamer gel. J Pharm Sci. 1997;86:1006-10.
76. Liu Y, Lu WL, Wang JC, Zhang X, Zhang H, Wang XQ, et al. Controlled delivery of recombinant hirudin based on thermo-sensitive pluronic® F127 hydrogel for subcutaneous administra-tion: in vitro and in vivo characterization. J Control Release. 2007;117:387-95.
77. Das N, Madan P, Lin S. Statistical optimization of insulin-loaded pluronic F-127 gels for buccal delivery of basal insulin. Pharm Dev Technol. 2012;17:363-74.
78. Bias P, Labrenz R, Rose P. Sustained-release dexamethasone palmitate: pharmacokinetics and efficacy in patients with activated inflammatory osteoarthritis of the knee. Clin Drug Investig. 2001;21:429-36.
79. Horisawa E, Hirota T, Kawazoe S, Yamada J, Yamamoto H, Takeuchi H, et al. Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm Res. 2002;19:403-10.
80. Larsen C, Ostergaard J, Larsen SW, Jensen H, Jacobsen S, Lindegaard C, et al. Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. J Pharm Sci. 2008;97:4622-54.
81. Patel ZS, Yamamoto M, Ueda H, Tabata Y, Mikos AG. Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2. Acta Biomater. 2008;4:1126-38.
82. Lee GS, Park JH, Shin US, Kim HW. Direct deposited porous scaffolds of calcium phosphate cement with alginate for drug delivery and bone tissue engineering. Acta Biomater. 2011;7:3178-86.
83. King WJ, Toepke MW, Murphy WL. Facile formation of dynamic hydrogel microspheres for triggered growth factor delivery. Acta Biomater. 2011;7:975-85.
84. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125:193-209.
85. Johnson OL, Cleland JL, Lee HJ, Charnis M, Duenas E, Jaworowicz W, et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med. 1996;2:795-9.
86. Yuksel E, Weinfeld AB, Cleek R, Waugh JM, Jensen J, Boutros S, et al. De novo adipose tissue generation through long-term, local delivery of insulin and insulin-like growth factor-1 by PLGA/PEG microspheres in an in vivo rat model: a novel concept and capability. Plast Reconstr Surg. 2000;105:1721-9.
87. Han K, Lee KD, Gao ZG, Park JS. Preparation and evaluation of poly(-lactic acid) microspheres containing rhEGF for chronic gastric ulcer healing. J Control Release. 2001;75:259-69.
88. Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci. 2010;99:2557-75.
89. Cai Q, Shi G, Bei J, Wang S. Enzymatic degradation behavior and mechanism of Poly(lactide-co-glycolide) foams by trypsin. Biomaterials. 2003;24:629-38.
90. Lavi G, Dinarello CA, Apte RN, Cohen S. Sustained release of IL-1Ra from biodegradable microspheres prolongs its IL-1-neutralizing effects. Israel J Chem. 2005;45:457-64.
91. Lavi G, Voronov E, Dinarello CA, Apte RN, Cohen S. Sustained delivery of IL-1Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases. J Control Release. 2007;123:123-30.
92. Gorth DJ, Mauck RL, Chiaro JA, Mohanraj B, Hebela NM, Dodge GR, et al. IL-1ra delivered from poly(lactic-co-glycolic acid) microspheres attenuates IL-1β-mediated degradation of nucleus pulposus in vitro. Arthritis Res Ther. 2012;14:R179.
93. Jain R, Shah N, Malick A, Rhodes C. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev Ind Pharm. 1998;24:703-27.
94. Fu K, Harrell R, Zinski K, Um C, Jaklenec A, Frazier J, et al. A potential approach for decreasing the burst effect of protein from PLGA microspheres. J Pharm Sci. 2003;92:1582-91.
95. Yuan W, Liu Z. Controlled-release and preserved bioactivity of proteins from (self-assembled) core-shell double-walled microspheres. Int J Nanomedicine. 2012;7:257-70.
96. van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 2000;17:1159-67.
97. Giteau A, Venier-Julienne MC, Aubert-Pouessel A, Benoit JP. How to achieve sustained and complete protein release from PLGA-based microparticles? Int J Pharm. 2008;350:14-26.
98. Rothstein SN, Federspiel WJ, Little SR. A simple model framework for the prediction of controlled release from hydrated biodegradable polymer matrices. J Mat Chem. 2008;18:1873-80.
99. Rothstein SN, Federspiel WJ, Little SR. A unified mathematical model for the prediction of controlled release from surface and bulk eroding polymer matrices. Biomaterials. 2009;30:1657-64.
100. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2:214-21.
101. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet. 2001;40:539-51.
102. Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev. 2002;28:13-6.
103. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. Hepatitis interventional therapy group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
104. Ferenci P. Peginterferon alfa-2a (40KD) (pegasys) for the treatment of patients with chronic hepatitis C. Int J Clin Pract. 2003;57:610-5.
105. Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui CH, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia. 2003;17:1583-8.
106. Molineux G. The design and development of Pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10:1235-44.
107. Yu P, Zheng C, Chen J, Zhang G, Liu Y, Suo X, et al. Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist. Bioorg Med Chem. 2007;15:5396-405.
108. Pettit DK, Bonnert TP, Eisenman J, Srinivasan S, Paxton R, Beers C, et al. Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. J Biol Chem. 1997;272:2312-8.
109. Lee S, Greenwald RB, McGuire J, Yang K, Shi C. Drug delivery systems employing 1,6-elimination: releasable poly(ethylene glycol) conjugates of proteins. Bioconjug Chem. 2001;12:163-9.
110. Jun JB, Kim JK, Kim TH, Na YI, Choi CH, Kim YH. Inhibition of the IL-1β-induced expression of matrix metal-loproteinases by controlled release of IL-1 receptor antagonist using injectable and thermo-reversible gels in human osteoarthritis chondrocytes. J Rheum Dis. 2011;18:85-93.
111. Poznansky MJ, Juliano RL. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol Rev. 1984;36:277-336.
112. Gombotz WR, Pettit DK. Biodegradable polymers for protein and peptide drug delivery. Bioconjug Chem. 1995;6:332-51.
113. Jin KM, Kim YH. Injectable, thermo-reversible and complex coacervate combination gels for protein drug delivery. J Control Release. 2008;127:249-56.
114. Whitmire RE, Wilson DS, Singh A, Levenston ME, Murthy N, García AJ. Self-assembling nanoparticles for intra-articular delivery of anti-inflammatory proteins. Biomaterials. 2012;33:7665-75.
115. Liang D, Fu X, Liao M, Yuan W, Su J. Development of dextran microparticles loaded with IL-1Ra of high-encapsulation efficiency and high-bioactivity by a novel method without exposing IL-1Ra to water-oil interfaces. Powder Technol. 2013;235:299-302.
116. Akash MSH, Rehman K, Li N, Gao JQ, Sun H, Chen S. Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs its therapeutic potentials. Pharm Res. 2012;29:3475-85.
117. Akash MSH, Rehman K, Sun H, Chen S. Assessment of release kinetics, stability and polymer interaction of PF127-based thermosensitive gel of IL-1Ra. Pharm Dev Technol. 2013. doi: 10.3109/10837450.2013775158.
118. Akash MSH, Rehman K, Chen S. Sustained delivery of IL-1Ra from PF127 gel reduces hyperglycemia in diabetic GK rats. PLoS One. 2013;8:e55925.
119. Barichello JM, Morishita M, Takayama K, Nagai T. Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats. Int J Pharm. 1999;184:189-98.
120. Johnston TP, Punjabi MA, Froelich CJ. Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm Res. 1992;9:425-34.
121. Katakam M, Bell LN, Banga AK. Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci. 1995;84:713-6.
122. Akash MSH, Rehman K, Rasool F, Sethi A, Abrar MA, Irshad A, et al. Alternate therapy of Type 2 diabetes mellitus (T2DM) with Nigella (Ranunculaceae). J Med Plants Res. 2011;5:6885-9.
123. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology. 2008;149:2208-18.
124. Ehses JA, Lacraz G, Giroix M, Schmidlin F, Coulaud J, Kassis N, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A. 2009;106:13998-4003.
125. Lacraz G, Giroix M, Kassis N, Coulaud J, Galinier A, Noll C, et al. Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 dia-betic GK rat. PLoS One. 2009;4:e6963.
126. Akash MSH, Rehman K, Sun H, Chen S. Interleukin-1 receptor antagonist improves normoglycemia and insulin sensitivity in diabetic GK-rats. Eur J Pharmacol. 2013;701:87-95.
127. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, et al. Interleukin-1 receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517-26.
128. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009;32:1663-8.
129. Akash MSH, Rehman K, Gillani Z, Sun H, Chen S. Cross-species comparison of IL-1Ra sequence between human and rat. J Proteomics Bioinform. 2013;6:38-42.